724 related articles for article (PubMed ID: 8617315)
1. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
2. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
3. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
4. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
5. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A; Schirmbeck R; Reimann J
Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
[TBL] [Abstract][Full Text] [Related]
8. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
9. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
10. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
11. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
Shirai M; Pendleton CD; Berzofsky JA
J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
13. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein.
Yellen-Shaw AJ; Wherry EJ; Dubois GC; Eisenlohr LC
J Immunol; 1997 Apr; 158(7):3227-34. PubMed ID: 9120278
[TBL] [Abstract][Full Text] [Related]
14. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
15. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
16. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Schott ME; Wells DT; Schlom J; Abrams SI
Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
[TBL] [Abstract][Full Text] [Related]
17. A self-reactive class I-restricted T-cell response of H-2b mice to determinants of the V beta 8.2 domain of the T-cell receptor for antigen.
Kuhröber A; Schirmbeck R; Reimann J
Immunology; 1994 Dec; 83(4):532-9. PubMed ID: 7533132
[TBL] [Abstract][Full Text] [Related]
18. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
[TBL] [Abstract][Full Text] [Related]
19. Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I-restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein.
Schoel B; Zügel U; Ruppert T; Kaufmann SH
Eur J Immunol; 1994 Dec; 24(12):3161-9. PubMed ID: 7805744
[TBL] [Abstract][Full Text] [Related]
20. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]